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 I 
Abstract 
 
Background 
Publication bias of clinical trials can lead to increased harms and costs for patients and society.  
Attempts to reduce publication bias and its effects have focused on increasing the transparency of 
conducting clinical trials.  The Food and Drug Administration Amendments of 2007 (FDAAA 2007) 
requires the registration of the results of applicable trials on ClinicalTrials.gov, a publicly accessible 
database.  It is unclear whether or not registering results of clinical trials will decrease publication bias 
by increasing rate of publication in a peer-reviewed journal. 
 
Methods 
I conducted a cross-sectional analysis of all clinical trials dealing with the primary treatment and/or 
prevention of cancer registered on ClinicalTrials.gov and completed from October 2007 to December 
2009.  I used Medline, Cochrane Library, EMBASE, and CINAHL to search for a corresponding publication 
for each of the included trials. I used a logistic regression model, adjusted for identified covariates, to 
examine the relationship between having registered results and having a corresponding publication.  
 
Results 
A total of 371 trials were included for the analysis.  When adjusted for enrollment size, study phase, and 
funding type, trials without registered results publish 66.2% of the time, and trials with registered 
results publish 72.9% of the time, p= 0.21.  In comparing the registered outcomes with the published 
ones, 120 of 124 trials (96.7%) reported the same primary outcome(s).  Of the 120 that reported the 
same primary outcomes, 12 (17.5%) showed discrepancies in the reported results and the published 
results.  Among the 128 trials with a corresponding publication, there does not appear to be a 
relationship between funding type and the probability of publishing a favorable outcome. 
 
Discussion 
Registering results by themselves does not increase the publication rate, and results alone do not 
provide enough information to adequately interpret and assess a clinical trial. There is a great need to 
expand FDAAA 2007 to require the registration of the full research protocols and summaries of clinical 
trials. 
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Background 
Publication bias is the act of not publishing studies with unfavorable results, selectively 
publishing favorable outcomes, and misrepresenting or misinterpreting data to make the results more 
favorable.  Publication bias can harm patients, impede the progress of medical knowledge, and 
substantially increase costs.  Since the proper practice of medicine is evidence-based, publication bias 
may begin a chain of events leading to an incomplete and/or biased body of evidence and, in practice, to 
prescribing ineffective or even harmful medicines.  Two well-publicized examples are Merck’s recall of 
Vioxx (an arthritis drug) due to its increased risk of causing cardiovascular disease and the surrounding 
debates about the concealment of these data; and the lawsuit against GlaxoSmithKline charging them 
for concealing the lack of efficacy data and increased likelihood of suicide associated with the use of 
Paxil (an antidepressant) (1).  Other cases include published literature demonstrating an overall 32% 
greater effect size of a range of antidepressants when compared to FDA-registered studies (2); and an 
analysis of previously unpublished studies of rosiglitazone (a diabetes drug) showing that it may cause a 
higher risk of myocardial infarction and death than had been previously reported (3). 
The lack of transparency in reporting clinical trials can also impede the progress of knowledge 
and increase the cost of health care.  If researchers mistakenly believe an effective treatment for a 
particular disease is already documented in the literature, they have few incentives to conduct further 
research.  Conversely, if researchers do not have a complete picture of conducted trials, they become 
more prone to repeating them.  Together with prescribing medicines that lack efficacy and may harm 
patients, repeating trials unnecessarily can add to the already burgeoning cost of health care.  Not 
conducting needed research, on the one hand, precludes the discovery of more effective therapies.  On 
the other hand, conducting unnecessary clinical trials means that the research itself can become a 
source of harm to patients.  
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In an effort to increase transparency in clinical trials and to curb publication bias, the 
International Committee of Medical Journal Editors (ICMJE) in 2005 required the registration of the 
characteristics of clinical trials before the start of the trials as a prerequisite for publishing in ICMJE-
associated journals (4).  From May to October 2005, trial registrations grew significantly in compliance 
with the new policy (5).  Building on ICMJE’s example, the Food and Drug Administration Amendments 
Act of 2007 included and expanded this requirement (FDAAA 2007)(6).  Among other changes, FDAAA 
2007 requires the registration on a dedicated website, ClinicalTrials.gov, of the results of applicable trials 
(phase II and beyond interventional studies; studies involving drugs, biologics, and medical devices 
regulated by the FDA; studies having at least one site in the United States or conducted under an 
investigational new drug application or investigational device exemption; and studies initiated after 
September 27, 2007 or ongoing as of December 27, 2007) within a set time frame after trial completion 
(7).  Failure to do so is met with substantial penalties, including a charge of $10,000/day for each day of 
non-compliance (7).  FDAAA 2007 makes the results of clinical trials publicly available regardless of 
whether the trials are published in a peer-reviewed journal.  Of important note, ICMJE acknowledges 
the complementary roles of registering results and publications and does not consider the former to be 
a previous publication (8).  
The registration of results is a great step toward increasing transparency.  However, the law 
simply requires the registration of the results (non-peer-reviewed), without their much needed 
accompanied commentaries and explanations.  Furthermore, in the absence of a full study protocol, the 
validity and reliability of the results become difficult to assess.  In inexperienced hands, results by 
themselves can harm more than help patients.  Thus, peer-reviewed publications remain crucial to our 
understanding of the results and implications of clinical trials.  Compared to trials registered in 
ClinicalTrials.gov and completed before 2007, trials registered and completed after 2007 generally have 
fewer missing data elements and have more results posted (9).  It is unknown whether this improved 
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transparency –making the results publicly available, removing the incentives to conceal or manipulate 
their presentation–increases the publication rates of clinical trials in peer-reviewed journals.                
This paper seeks to measure the effects of FDAAA 2007 on publication bias by addressing this 
question;  Compared to clinical trials without registered results, do clinical trials with registered results 
have a higher rate of publication in a peer-reviewed journal?  The inquiry also yields two related 
secondary questions:  For trials with registered results and a corresponding publication, how well do the 
results of the registered primary outcome(s) match with the published results?  And for all trials with a 
corresponding publication, is there a relationship between funding type and whether a trial is more 
likely to favor the experimental arm (i.e. drug or biologic)?  I limit the present test of these questions to 
clinical trials of the primary treatment or prevention of cancer because cancer is a leading cause of 
morbidity and mortality, and drugs and biologics used to treat cancer tend to create a heavy price 
burden for patients.     
 
Methods 
Selection of Trials 
With the goal of capturing as many completed trials with registered results as possible, I 
searched ClinicalTrials.gov on 03/03/2012 with the following limits and terms: closed studies 
(recruitment has ended), exclude unknown recruitment status, interventional studies, neoplasm, 
biologic OR drug, phase II, III, IV, NIH, US Fed, industry, other, and received from 03/29/2000 to 
12/31/2011.  This search strategy captures all interventional trials involving the treatment or prevention 
of cancer with either a drug or biologic, from all phases beyond I, with any funding source, and 
registered at the inception at ClinicalTrials.gov and beyond.  I then abstracted the retrieved trials with 
their registered characteristics (NCT number, title, recruitment status, having results or no, condition 
examined, funding type, drug or biologic studied, phase, enrollment size, completion date, etc.) into 
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Microsoft Excel.  I then filtered the trials to include only those with a primary completion date and 
completion date between October 2007 and December 2009 (to allow two years to post results and to 
publish, and FDAAA 2007 only applies to studies completed after late September 2007).  I sorted the 
resulting trials into two cohorts: those with registered results and those without registered results.  For 
the trials without results, I used a random number generator to choose a starting point, and sampled 
every 3rd trial to obtain a relatively even number of trials in each cohort.           
 
Searching for Publications    
I searched for a corresponding publication for each trial using a systematic approach adapted from 
Bourgeois and his colleagues (10).  In particular, I searched the same databases, allowed at least two 
years for the completed trials to get published, and used their strategy of searching using key words 
derived from the drug(s) and/or biologic(s), investigators, and disease of interest being studied for each 
clinical trial.  During this search, I excluded trials studying the treatment of the secondary symptoms of 
cancer (e.g. anemia, imaging, pain, etc.) and those that were terminated, withdrawn or suspended.   I 
first looked at ClinicalTrails.gov to see if it cited a publication for the trial.  If ClinicalTrials.gov did not 
include such information, I proceeded to search Medline with the CinicalTrials.gov identification 
number.   If this did not produce a publication, I searched for the trial Principal Investigator’s (last 
name), the trial condition (i.e. cancer type), and the drug or biologic of interest.  If I found a potential 
article, I matched its characteristics with the descriptors of the trial, including location, enrollment 
number, primary and secondary outcomes, doses of the drug, etc.  
If I could not find an article after using this strategy, I repeated these steps in searching Medline, in 
the Cochrane Library, Embase (a biomedical database that contains many records from Medline and 
beyond), and the Cumulative Index to Nursing and Allied Health Literature (CINHAL).  If the search of 
these last three databases also failed to find an article, I concluded that there is no publication for that 
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trial.  I saved all publications I did find using the clinicaltrials.gov ID number as an identifier.  To make 
sure that I was not giving undue time for publication to some trials but not others, I censored the 
publication data with an endpoint of February 29th, 2012 (e.g. an article published after that date is 
considered as not having a publication).  Figure 1 shows the selection process and the number of trials 
this process produced. 
 
Searching for FDA Approval 
To determine the FDA approval status of the drug and/or biologic used in each trial, I searched 
the FDA site at http://www.accessdata.fda.gov/scripts/cder/drugsatfda/.  The search engine of this 
particular segment of the site does not cover biologics, so if the initial search turned up nothing, I 
searched the entire FDA site broadly.  If an experimental drug did not have a name, I used a drug portal 
from the national library of medicine (http://druginfo.nlm.nih.gov/drugportal/drugportal.jsp) to check 
for corresponding names.  Often times, each drug has multiple names and labels.  In such situations I 
downloaded all the labels into a common directory.  If it happened that the FDA did not have a single 
label for the drug of interest, I used Google and the National Cancer Institute to identify the relevant 
information.  To determine FDA approval, I matched the formulation (i.e. injection vs. PO or x-month 
depot) and the disease for which the drug and/or biologic is being used with the indications and use 
found in FDA drug and/or biologic label(s).  All drugs and/or biologics in the trial needed to be FDA 
approved before I considered the entire trial to be considered “FDA approved”. 
 
Matching Registered with Published Outcomes 
For the subset of studies with registered results and a corresponding publication, I compared 
the numerical results of registered primary outcome(s) with the published one(s).  For each trial, I noted 
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if the publication reported the same outcome(s) as did the registered trial.  I then determined if the 
results of the published outcome(s) match the results of the registered outcome(s).  
 
Determining the Influence of Funding and Favorable Outcomes 
For the subset of trials with a corresponding publication, I examined whether the publication 
favors the experimental drug/arm for the primary outcome(s).  This data subset included all the 300 
trials without registered results that had a corresponding publication and a random 33% sample of the 
initial 339 trials with registered results with a corresponding publication. This method gives a more 
representative sample of all trials completed from October 2007 to December 2009.  For trials with a 
single arm and without a test of statistical significance, I based my judgment on the authors’ conclusion.  
In such cases, I considered terms such “promising” and “encouraging” as favorable and “modest” and 
“moderate” as unfavorable.  For trials with multiple arms, I looked for a statistically significant 
difference between the arms in the primary outcome of interest.  
 
Creating a Trials Codebook 
Table 1 shows the definitions and values of all coded variables.  I coded funding in two different 
ways: into six different categories as classified by ClinicalTrials.gov (other [e.g. universities or non-profit 
organizations], US federal government, solely NIH, solely industry, other/NIH, industry/other, and 
other/industry/NIH) and into two categories (without any funding from industry and with partial or 
complete funding from industry).  I coded masking and intervention design dichotomously as well 
because few trials used single or triple masking (compared to double) and cross-over design (compared 
to parallel arm).  I coded time from completion date and primary completion date to time of the 
publication in months.  I used the end of the month posted on ClinicalTrials.gov and calculated the time 
elapsed from then to the end of February 2012 (the time of our publication search). 
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 A colleague, Dane Meredith, repeated an analysis of a random 10% (64) subset of the original 
639 trials to determine if they were relevant, marked as completed, or had a corresponding publication.  
I disagreed on the classification of 5 (7.8%) of the trials.  After discussion, I was not required to change 
my initial classification of any trials.   
 
Statistical Analysis 
I used Stata 12.0 (College Station, Texas) to analyze the data.  The outcome for the primary 
research question is a publication that corresponds to the trial.  The main independent variable for this 
analysis is having registered results.  I included additional variables in the analysis in order to assess their  
potential to confound the relationship between registered results and corresponding publication.  These 
other variables are enrollment size, phase of the clinical trial, funding source, intervention design, 
allocation type (randomized or not), the use of masking, having one or multiple study sites, having a US 
study site, FDA approval status, the time (in months) elapsed from completing the data collection for the 
primary outcome to the date of our publication search, and the time elapsed from trial completion to 
the date of my publication search. 
I first generated frequency distributions of all variables to examine the characteristics of the 
trials and to assess the effects of missing data and extreme values.  Given the non-parametric 
distribution of our continuous variables, I used the Wilcoxon Rank-Sum tests to report the medians and 
Pearson’s chi-square tests to tabulate the characteristics of categorical variables.  Then I conducted 
bivariate analyses to identify the relationship between the variables and the primary outcome and the 
main independent variable.  I used Pearson’s correlation for continuous variable (enrollment size and 
time in months from trial completion to date of publication search) and Pearson’s chi-square test to 
examine the relationship between the primary outcome and the main independent variable for each 
categorical variable. I then used a logistic regression model to examine our relationship of interest, 
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adjusted for covariates identified from the bivariate analyses.  The data dictated treating trial phase and 
funding type as nominal variables; in particular, because only three trials were either entirely funded by 
the federal government or by a combination of industry, NIH, and other sources.   The final logistic 
regression model adjusts for enrollment size, trial phases, and funding type, and it drops an additional 
two observations for which trial enrollment size data are missing.  A two-sided sample size calculation 
with alpha=0.05 estimated that I would need a total of 330 trials to have a power of 0.80 to detect a 
15% difference in publication status.  
I used a similar approach to analyze the relationship between reporting a favorable conclusion 
(outcome of interest) and funding type (main independent variable).  Since a favorable conclusion leads 
to FDA approval (FDA approval status lies on the causal pathway), I did not adjust for FDA approval.  In 
the final model, I also adjusted for randomization and intervention design.  The test of how well 
registered and published outcomes match results from a careful comparison of the two reported sets of 
findings for any apparent discrepancy, including any presentation that appears to emphasize a more 
favorable result in publication than was evident in the registered results; see the next section for 
examples. 
 
Results 
The initial search criteria retrieved 8946 trials.  Including only trials completed between October 
2007 and December 2009, including all the trials completed in this period that had registered results, 
and randomly sampling every 3rd trial without registered results (to yield an approximately equal 
number of trials with and without registered results), yielded 639 trials, of which 300 did not have 
registered results.  The application of all exclusion criteria produced a final sample of, 371 relevant, 
completed trials (Figure 1), of which 174 are in the “no registered results” group, and 197 are in the 
“registered results” group .  Table 2 shows the overall characteristics of the 371 trials:  58.8% have a 
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corresponding publication; the trials enrolled a median of 59 patients; and more than half of them were 
in phase IIAs the table makes clear, a large majority of the trials (89%) did not use any form of masking 
and almost three quarters of them were funded in part or in whole by industry.  More than half of the 
trials had a single group assignment (i.e. single arm in the study), and the sample does not appear to be 
affected by any right censoring in terms of time to publication for trials completed by 2009 (83 and 85 
trials completed by 2008 and 2009 had a corresponding publication, respectively).  
Tables 3 and 4 show that trials with registered results had more patients enrolled (77 vs. 46), 
and they were more likely to be funded solely by industry (70.3% vs. 28.6%).  This disparity most likely 
results from the fact that the overwhelming preponderance of trials in the entire sample is industry-
sponsored.  Registered trials were more likely to be of drugs with FDA approval (37.4% vs. 12.5%), and a 
greater proportion of registered trials had more than one study site (70.2 vs. 53.6%). Statistically 
significant covariates included the phases of the trial, the enrollment size, and the funding type; funding 
type may be significant because of the maldistribution of the data.  Table 5 shows, ceteris paribus, an 
almost 10% differential in publication, favoring trials with published results; this difference is rendered 
insignificant by controlling for enrollment size, study phase, and funding type.  Almost all registered 
trials, 120 of 124, reported the same primary outcome(s) in the registry as they did in their 
corresponding publication.  Of the four trials that did not report the same primary outcome(s), one trial 
did not report the results for one arm of its trials; one trial did not report the second stage of its trial; 
one trial, with very confusing registered primary outcomes, did not report all of its primary outcomes; 
and the remaining trial was included as a part of a pooled analysis and did not report the primary 
outcome of the separate trial.  
 Of the 120 trials that did report the same primary outcomes, 21 (17.5%) showed apparent 
discrepancies between the registered and published results.  Of these 21 trials, 8 (38.1%) published 
results that seem to improve the efficacy of the experimental drug/biologic;  8 (38.1%) published results 
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that seem to lower the efficacy of the experimental drug/biologic; and 5 (23.8%) published different 
numbers, and could not be determined to improve or reduce the efficacy of the experiment 
drug/biologic. 
Among the 128 trials with a corresponding publication, unadjusted analysis examining the 
relationship between funding type and publishing a favorable outcome shows no difference between 
having partial or complete funding by industry and having no funding from industry (62.7% vs. 62.3% 
favorable, p=0.96).  Table 6 shows that adjusting for randomization of patients and the intervention 
model does not materially change the results, and when funding type is broken into the six different 
categories found on ClinicalTrials.gov, the number of trials in each category becomes too few to make a 
clear conclusion.  Overall, however, it does not appear that funding type affects the probability of 
publishing a favorable outcome (Supplementary Table 2, in Appendix A).   
 
Discussion 
Our study suggests that while a law like FDAAA 2007 does increase the transparency of clinical 
trials, the increased transparency gained from the registration of the results of clinical trials does not 
appear to be accompanied by an increase in the rate of publication in a peer-reviewed journal, at least 
in the first years of implementation of this policy change, from 2007 to 2009.  Clinical trials of drugs or 
biologics in the primary treatment or prevention of cancer were published in peer-reviewed journals at 
roughly the same rate regardless of whether the trials were registered on ClinicalTrials.gov.  . While we 
have no benchmark against which to compare the effects of FDAAA 2007 on publication bias, even if the 
7% difference in publication rate were statistically significant, it is unlikely to demonstrate meaningful 
change resulting from the policy, at least in its early years.  Other potential confounders in the group of 
trials could also explain this difference.  Prayle and colleagues found that only 22% of trials that were 
required to be reported, actually did report their results within the required time frame (11).  Just as 
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people have always suspected about publication bias, it is possible that trials with more favorable 
findings are more likely to be registered and published.  This unquantifiable confounder could 
potentially explain the higher, albeit statistically insignificant, publication rate of trials with registered 
results.    
The sampling strategy used to answer the primary question in this work may affect the 
representativeness of the publication rates.   However, a body of literature does show that 
approximately 30% of trials do remain unpublished, even several years after their completion (12).  This 
suggests that even after FDAAA 2007, the failure to publish the results of clinical trials remains a large 
problem.   
Furthermore, while ClinicalTrials.gov does employ quality control measures to verify the data 
entered into its database and to detect blatantly incorrect data, such as ages of several hundred years, it 
currently does not and cannot verify the accuracy of the entered data that are within apparently normal 
ranges (13).  This great responsibility for data accuracy remains with the sponsors and investigators of 
the clinical trials.  In the subset of trials with registered results and a corresponding publication, 96.7% of 
the trials register and publish the same primary outcomes.  However, only 83.5% of the registered 
primary outcome results match the outcome results in the corresponding publications.  These 
discrepancies do not appear to be systematic:  38.1% of discrepancies are more favorable, 38.1% are 
less favorable, and 23.8% cannot be compared to the published results, respectively.   
Researchers noted similar discrepancies in a study comparing the registered primary outcomes 
with published ones for randomized controlled trials in cardiology, rheumatology, and gastroenterology 
(14). The authors found that of the 147 adequately registered trials with a corresponding publication 
indexed in 2008, 46 (31%) show some evidence of discrepancies between the registered and published 
outcomes (14).   While the authors could only assess the influence of the discrepancies in half of the 46 
studies, they found that 19 (82.6%) of those 23 studies favored statistically significant results (14).  
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Although the discrepancies in the oncology trials examined here do not appear to vary in systematic 
ways, they do call for a re-analysis of validity of the registered results, especially if the results without 
their accompanied commentaries and explanations and research protocols are to be taken at face value 
and used to guide the treatment of patients.   
The finding here of no relationship between funding type and the probability of reporting a 
favorable outcome for the experimental drug or biologic (62.8% vs. 59.6%, p=0.76) does not agree with 
previously published literature.  One study examining drug trials registered in ClinicalTrials.gov as of 
August 2009 involving five categories of drugs (not including oncology drugs), for example, found that 
85.4% of publications from industry-funded trials reported favorable outcomes, compared with 50.0% of 
publications among government-funded trials and 71.9% among nonprofit or nonfederal source-funded 
trials (10).  Further, after reclassifying nonprofit or nonfederal source-funded trials into those that also 
received industry contributions and those without industry contribution, 85.0% of publications of trials 
with industry support in that study reported favorable outcomes, true of only  62.1% of those without 
industry support (10).  These data suggest a strong relationship between having any industry 
contribution and the probability of a publication reporting a favorable outcome.  Perhaps the different 
pattern of findings reported in this current study comes from the difference in diseases examined 
and/or the smaller sample of oncology trials examined.    
 
Limitations  
Since the included trials only examine the primary treatment or prevention of cancer, the results 
here may not be readily generalizable to other medical conditions.  Because an attempt to include only 
those trials required to register their results by law yielded too few trials without registered results for a 
meaningful analysis, my primary question was not limited to trials with a mandatory reporting 
requirement.  That inability to identify a sufficient number of trials with mandatory reporting status 
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stems from using only FDA approval status, and not both FDA approval and Investigation New Drug 
(IND) application status.  According to FDAAA 2007, drugs and biologics under an IND application must 
also report their results (7), but its confidentiality makes the IND application status difficult to 
determine.  Furthermore, since the final sample size was only powered to detect a 15% difference in 
publication status, a smaller, but statistically significant difference could have been detected with a 
larger sample size.  Additionally, while I developed a robust method for searching for a corresponding 
publication in four major publication databases, it remains possible that I misclassified some trials, and 
publications could have been found in other databases. 
This analysis of the relationship between funding type and the probability of publishing a 
favorable outcome dichotomizes funding type into any or complete funding from industry, and no 
funding from industry, to preserve sufficient cases per category for adequate analysis.  To determine 
whether this collapsing of funding categories affected the results, I re-ran them, adding a “partial 
industry funding” category, generating similar results.  Finally, the results here may not be generalizable 
to trials registered outside of ClinicalTrials.gov.  Future studies should examine these questions in other 
medical conditions and other trial registries.     
 
Policy Implications 
Clinical trials with positive results tend to be published more often than do trials with negative 
results (4).  Despite ICMJE’s statement calling for the publication of negative clinical trials, a large 
proportion of trials overall remains unpublished (15).  Even an attempt to increase the transparency of 
clinical trials by requiring them to register their results does not appear to increase the publication rate.  
Perhaps certain policy makers had foreseen this, as FDAAA 2007 also includes a provision to expand the 
registry and results database by developing implementation rules within three years from the 
enactment of FDAAA 2007(7).  The law states that this rulemaking process will elaborate the definitions 
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and requirements of FDAAA 2007 and address the possibility of also requiring trials with unapproved 
products to register their results; investigators and/sponsors to provide non-technical and technical 
summaries of the clinical trials and their results for patients and researchers, respectively; investigators 
and/or sponsors to provide the full protocol of the trial; and anything else deemed appropriate since the 
enactment of FDAAA 2007 (7).  Although a public meeting did occur on April 20, 2009 to provide an 
opportunity for input from interested parties about the regulations for the expanded registry and results 
database, final rules have not yet been issued (16, 17).  
Given that isolated results do not provide sufficient information fully to understand a clinical 
trial, and the requirement to register results does not appear to reduce publication bias, an expanded 
registry and results database that includes a full protocol of the trial and summaries for patients and 
researchers becomes crucial.    Such an expanded database would allow for the effective dissemination 
and acquisition of knowledge regardless of whether a trial publishes in a peer-reviewed journal for 
whatever reason.  Since ICMJE will only release registrations from the “no prior publication” 
requirement if they have fewer than 500 words, some trials that comply with the updated FDAAA 2007 
law may be prevented from publishing in a peer-reviewed journal (8).  A possible solution is to allow for 
a publication in lieu of an expanded results registration.  Alternatively, ICMJE can exempt trials that 
register from their policy, or relax its policy in a manner that does not disincentivize trials from fully 
registering their results. 
To protect patients, FDAAA 2007 has required applicable clinical trials to report adverse events 
during the study period since September 2009 (7).  An expanded registry and results database can be 
seen as an extension of the requirement to protect patients, since isolated results are more likely to be 
misinterpreted in insufficiently trained hands.  Furthermore, systematic reviews and meta-analyses 
require more than just results to synthesize previous research into the existing body of evidence.  
Incorporation of a methodologically weak trial, one that could not be assessed for robustness due to the 
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lack of sufficient information provided, into a review can bias the review’s overall conclusions and 
weaken its scientific integrity.  A biased body of evidence does not benefit patients. 
Although the requirement to register summaries and protocols in addition to results may create 
additional burdens on investigators and/or sponsors, they have the moral and financial obligation to do 
so.  Participants volunteer in clinical trials despite uncertain benefits and possible harms to advance 
knowledge, and in the hope  that this knowledge will benefit as many people as possible.  The failure to 
provide such knowledge in a complete and comprehensible form to all those who can benefit from it is a 
disservice to the hopes and wishes of the participants in the trials.  Additionally, funding for trials 
conducted by academia and other non-profit organizations come from taxpayers’ money.  The public 
has a right to the information they are paying for.           
Regardless of whether the law will begin to require a more complete registration of the results 
of the clinical trials, it will remain extremely difficult if not impossible for those not directly involved with 
the conduct of the trials to verify the validity and reliability of the data.  As such, everyone involved in 
any step of a clinical trial must collaborate with researchers and non-researchers to continue to commit 
to the high levels of honesty and integrity needed in the fields of medical sciences and beyond.  Only 
with these steps can we truly hope to improve the health of our patients.   
 
 
 
 
 
 
 
 
 
 
 
  
 16 
 
Figure 1: Selection of Trials 
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Table 1: Codebook 
Variable (Name) Coded as 
Registered Results (Result) Does Not Have Registered Results=0 
Has Registered Results=1 
Study Phase (Phase) I/II=0 
II=1 
II/III=2 
III=3 
IV=4 
Enrollment Size (Enroll) Number 
Funding Type in Six Categories (Fund) Other=0 
US Fed=1 
NIH=2 
Industry=3 
Other/NIH=4 
Industry/Other=5 
Other/Industry/NIH=6 
Funding Type in Two Categories (Indus) No Funding by Industry=0 
Any Funding by industry=1 
Allocation (Allo) Non-Randomized=0 
Randomized=1 
Intervention Model in Two Categories (Mod) Single Group Assignment=0 
Parallel Group Assignment or Cross-Over Design=1 
Masking in Two Categories (Blind) Open=0 
Single or Double or Triple=1 
Number of Study Sites (Site) Single Study Site=0 
Multiple Study Sites=1 
US Study Site (US) Not Having a US Study Site=0 
Having a US Study Site=1 
FDA Approval Status (FDA) No=0 
Yes=1 
Time Elapsed Since Primary Completion Date 
(Primary) 
In Number of Months 
Time Elapsed Since Completion Date (Comp) In Number of Months 
Corresponding Publication (Pub) Does Not Have a Corresponding Publication=0 
Has a Corresponding Publication=1 
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Table 2: Characteristics of the Included Trials 
Characteristic (n=371) Median or Percent 
% Having a Publication 58.8 
% Having Registered Results 52.6 
Enrollment Size 59 
% of Trials in Phase 
                 I/II 
                 II 
                II/III 
                III 
                IV 
 
10.0 
66.3 
2.3 
18.9 
2.7 
% of Trials Using Masking 
               Open 
               Single-Blind 
               Double-Blind 
               Triple-Blind 
 
89.3 
0.8 
7.7 
2.2 
% of Trials Funded by 
              Other* 
              US Federal Government 
              NIH 
              NIH/Other 
              Industry 
              Industry/Other 
              Industry/Other/NIH      
 
17.3 
0.3 
2.4 
8.1 
55.3 
16.2 
0.5 
%Funded Fully or in Part by Industry 72.0 
% of Trials with FDA approved drugs/biologics 25.6 
%Using Randomization of Patients 41.6 
% of Trials Using Intervention Model 
             Single Arm 
             Parallel Arm 
             Cross-Over 
 
58.4 
39.9 
1.7 
% Having More than One Arm 41.6 
%Having More than One Study Site 62.1 
% Having One or More Study Site in the US 64.5 
Months Elapsed Since Primary Completion Date 
and Publication Search 
40 
Months Elapsed Since Completion Date and 
Publication Search 
37 
*Other includes academic institutions and other non-profit organizations 
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Table 3: Bivariate Associations between Characteristics of the Sample and Having a Publication 
Characteristic N % Having a Publication 
or Correlation 
P value* 
Registered Results 
                 No 
                 Yes 
 
176 
195 
 
54.0 
63.1 
 
0.08 
Enrollment Size 371 0.11 0.03 
Trials in Phase 
                 I/II 
                 II 
                II/III 
                III 
                IV 
 
37 
246 
8 
70 
10 
 
54.1 
58.9 
12.5 
68.6 
40.0 
 
0.02 
Trials Using Masking 
               Open 
               Single, double, or triple masking 
 
325 
38 
 
 
58.8 
63.2 
 
0.60 
Trials Funded by 
              Other 
              US Federal Government 
              NIH 
              NIH/Other 
              Industry 
              Industry/Other 
              Industry/Other/NIH      
 
64 
1 
9 
30 
205 
60 
2 
 
57.8 
100 
22.2 
66.7 
55.6 
70.0 
100 
 
0.07 
Having FDA Approval Status 
                 No 
                 Yes 
 
276 
95 
 
57.3 
63.2 
 
0.31 
Using Randomization of Patients 
                 No 
                 Yes 
 
184 
131 
 
57.6 
67.2 
 
0.14 
Having More than One Arm 
                 No 
                 Yes 
 
212 
151 
 
56.1 
63.6 
 
0.16 
Having More than One Study Site 
                 No 
                 Yes 
 
130 
213 
 
59.2 
59.6 
 
0.94 
Having One or More Study Site in the US 
                 No 
                 Yes 
 
122 
222 
 
61.5 
58.1 
 
0.54 
Months Elapsed Since Primary Completion Date 
and Publication Search 
371 0.03 0.51 
Months Elapsed Since Completion Date and 
Publication Search 
371 0.05 0.37 
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* Medians and p values based on Wilcoxon Rank Sum for continuous variables and Pearson’s chi-
square test for categorical variable; Correlations and p values based on Pearson’s correlation 
Table 4: Characteristics Stratified by Having Registered Results # 
 
# Significance tests for comparisons based on Wilcoxon Rank Sum for continuous variables and 
Pearson’s chi-square test for categorical variables 
  **p<0.01 
 
Characteristic No Registered Results (n=176)  Has Registered Results (n=195) 
Median Enrollment Size** 46 77 
% of Trials in Phase** 
                 I/II 
                 II 
                II/III 
                III 
                IV 
 
14.2 
68.2 
2.8 
12.5 
2.3 
 
6.2 
64.6 
1.5 
24.6 
3.1 
Trials Using Masking 
               Open 
               Single, Double, or Triple  
 
89.5 
1.2 
 
 
88.3 
1.0 
Trials Funded by** 
              Other 
              US Federal Government 
              NIH 
              NIH/Other 
              Industry 
              Industry/Other 
              Industry/Other/NIH      
 
30.7 
0.6 
3.4 
9.7 
38.6 
17.1 
0 
 
5.1 
0 
1.5 
6.7 
70.3 
15.4 
1.0 
% With FDA Approval** 12.5 37.4 
%Using Randomization of 
Patients 
40.2 42.7 
% Having More than One Arm 36.3 46.2 
%Having More than One Study 
Site** 
53.6 70.2 
% Having One or More Study Site 
in the US 
60.5 68.4 
Median Months Elapsed Since 
Primary Completion Date and 
Publication Search  
40 40 
Median Months Elapsed Since 
Completion Date and Publication 
Search  
37 37 
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Table 5: Adjusted Comparison of Having Registered Results and the Probability of Having an Associated 
Publication 
 N % Having a Publication P value 
Unadjusted: 
      No Registered Results 
      Has Registered Results 
 
 
176 
195 
 
54.0 
63.1 
 
0.08 
Adjusted*: 
      No Registered Results 
      Has Registered Results 
 
 
173 
193 
 
66.2 
72.9 
 
0.21 
* Based on a multiple logistic regression model, adjusted for enrollment size, study phase, and funding 
type 
 
 
Table 6: Adjusted Comparison of Probability of Reporting a Favorable Outcome and Funding Type (2 
Categories) 
 N % With a 
Favorable 
Conclusion 
P value 
Unadjusted: 
      Not Funded by Industry  
      Partially or Completely funded by Industry   
 
53 
75 
 
62.3 
62.7 
 
0.96 
Adjusted*: 
      Not Funded by Industry  
      Partially or Completely funded by Industry   
 
35 
73 
 
59.6 
62.8 
 
0.76 
* Based on a multiple logistic regression model, adjusted for randomization and intervention model 
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Appendix A: Supplementary Tables 
S1: Bivariate Associations between Characteristics of the Sample and Reporting a Favorable Outcome 
Characteristic N % With a Favorable 
Conclusion or 
Correlation 
P value* 
Registered Results 
                 No 
                 Yes 
 
92 
36 
 
58.7 
72.2 
 
0.16 
Enrollment Size 128 0.04 0.66 
Trials in Phase 
                 I/II 
                 II 
                II/III 
                III 
                IV 
 
17 
86 
0 
23 
2 
 
64.7 
64.0 
NA 
56.5 
50.0 
 
0.90 
Trials Using Masking 
               Open 
               Single, double, or triple masking 
 
113 
12 
 
 
63.7 
50 
 
0.12 
Trials Funded by 
              Other 
              US Federal Government 
              NIH 
              NIH/Other 
              Industry 
              Industry/Other 
              Industry/Other/NIH      
 
35 
1 
2 
15 
52 
23 
0 
 
68.6 
100.0 
50.0 
46.7 
65.4 
56.5 
NA 
 
0.64 
Having Partial or Complete Industry Funding 
                 No 
                 Yes 
 
53 
75 
 
62.3 
62.7 
 
0.96 
Having FDA Approval Status 
                 No 
                 Yes 
 
99 
29 
 
56.6 
82.8 
 
0.01 
Using Randomization of Patients 
                 No 
                 Yes 
 
57 
51 
 
70.2 
51.0 
 
0.04 
Having More than One Arm 
                 No 
                 Yes 
 
70 
55 
 
72.9 
50.9 
 
0.01 
Having More than One Study Site 
                 No 
                 Yes 
 
48 
75 
 
56.3 
66.9 
 
0.24 
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Having One or More Study Site in the US 
                 No 
                 Yes 
 
49 
74 
 
69.4 
58.1 
 
0.21 
Months Elapsed Since Primary Completion Date 
and Publication Search 
371 -0.10 0.27 
Months Elapsed Since Completion Date and 
Publication Search 
371 -0.12 0.17 
* Medians and p values based on Wilcoxon Rank Sum for continuous variables and Pearson’s chi-
square test for categorical variable; Correlations and p values based on Pearson’s correlation 
 
S2: Adjusted Comparison of Probability of Reporting a Favorable Outcome and Funding Type (6 
Categories) 
 N % With a 
Favorable 
Conclusion 
P value 
Unadjusted: 
      Trials funded by 
              Other 
              US Federal Government 
              NIH 
              NIH/Other 
              Industry 
              Industry/Other  
              Industry/Other/NIH      
 
 
35 
1 
2 
15 
52 
23 
0 
 
 
68.7 
NA 
NA 
46.7 
65.4 
56.5 
NA 
 
 
0.60 
Adjusted*: 
      Trials funded by 
              Other 
              US Federal Government 
              NIH 
              NIH/Other 
              Industry 
              Industry/Other 
              Industry/Other/NIH      
 
 
26 
1 
0 
8 
50 
23 
0 
 
 
61.5 
NA 
NA 
49.8 
67.2 
52.9 
NA 
 
0.64 
* Based on a multiple logistic regression model, adjusted for randomization and intervention model 
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APPENDIX B: Systematic Review 
 
Background 
The purpose of medical research is to advance knowledge and develop effective therapies to 
manage illnesses.  One of the ways to achieve this aim is to ensure that knowledge is unbiased.  Not only 
does biased knowledge impede advancement, it results in suboptimal management of a patient’s well-
being.  Concurrent with the rapid growth of medical research, industry’s involvement in research has 
increased drastically.  In one analysis, during 1981-1984, less than 10% of investigators received some 
form of funding by industry, but by 1997-2000, over 60% of investigators did (1).  The rise in prevalence 
of industry-sponsored research has prompted concerns about conflict of interest.  Conflict of interest 
can lead to biased medical knowledge. 
Selectively publishing, publishing only favorable results and/or not publishing at all, can lead to 
biased medical knowledge.  By publishing selectively, investigators and sponsors can create an 
incomplete and inaccurate picture of the actual effectiveness of their drug product.  In a meta-analysis 
assessing the efficacy of anti-depressants, Whittington, Kendall, Fonagy, et al. found that if they include 
results from trials not published, the efficacy of many anti-depressants become negligible (2).  This 
inaccurate picture impedes the proper advancement of knowledge, hurts patients, and is a disservice to 
the volunteers who participated in the trials. 
Given the rising prevalence of industry-sponsored clinical trials and the harmful effects 
publishing selectively can have, it becomes important to examine the relationship between funding 
source and publishing.  This small systematic review will provide an overview of the publication 
characteristics of industry sponsored drug clinical trials compared to non-industry sponsored ones. 
 
 26 
 
 
Methods 
Defining the Focused Question 
I used the adapted population-intervention-comparator-outcome-time interval for search 
(PICOT) framework to define my focused question: compared to non-industry-sponsored clinical trials of 
drugs, are industry-sponsored clinical trials of drugs more selectively published?  Since the editors of the 
major journals did not require the disclosure of funding sources until late 2001, I limited my analysis to 
the year 2002 and later (3).  Given the nature of this question, cross-sectional studies become the most 
feasible research design to examine it.   
Category Inclusion Criteria Exclusion Criteria 
Population Clinical trials of drug  Non-clinical trials, not drug 
related 
Intervention/Exposure Having financial support from 
industry 
Not applicable 
Comparator Having no financial support from 
industry 
Not applicable 
Outcomes Publishing selectively Characteristics  
Time Interval for Search 2002-Present Before 2002 
Table 1: Defining the PICOT Framework  
 
Search Methods and Selection of Studies 
To identify literature published for this focused question, I searched PubMed using string 
“publication bias industry drug trial”, where “publication bias” and “industry” are MeSH terms.  I 
supplemented this search with suggested articles from an expert.  I wanted articles examining primary 
data, so I excluded reviews, commentaries, and editorials.  Since I wanted a broad picture of publication 
bias, I also excluded articles that only included one disease or one category of disease and articles 
examining fewer than three drug categories.   
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For the articles retrieved from the string above, I first looked at their titles to determine their 
relevance.  After excluding articles that did not have the relevant search terms and were not written in 
English, I read the abstracts of the remaining articles to make sure the studies simultaneously examined 
the role of industry and non-industry sponsorship as the primary or secondary outcome.   For articles 
that I could not glean the necessary information from the abstract, I obtained the full-text and read its 
methods section.   
 
Data Collection and Quality Assessment 
I collected relevant study characteristics from the seven studies into a table.  Using the same 
table, I also appraised each study’s internal validity and generalizability.  For internal validity, I focused 
primarily on selection bias, measurement bias, and potential for confounding.  I focused my analysis of 
selection bias primarily on how well the characteristics of the clinical trials, with the exception of 
funding type, resemble each other.  Measurement bias deals with masking and the equality, validity, and 
reliability of evaluative criteria.  Potential for confounding has to do with the possibility of other 
variables influencing both the main exposure and the outcome.   I used a plus system, where “+” 
represents minimum bias or potential and “+++” represents maximum bias or potential.  
Overall, I graded internal validity and generalizability on a scale of poor-fair-good (Tables 2 and 
3).  A “poor” for internal validity represents significant methodological flaws that significantly reduce the 
credibility of the results.  A “good” for internal validity represents a study with a strong research design 
that lends much credibility to its results.  A “poor” for generalizability represents results that cannot be 
applied outside of the clinical trials or publications examined in the articles.  A “good” for generalizability 
represents results that can be readily applied to many clinical studies or publications beyond the ones 
the articles examined (Table 3).  Using the study characteristics and my grading criteria, I looked for 
patterns to explain discrepancies in results and arrived at a final conclusion.   
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Grade Definition 
Internal validity is rated “good” if: Minimal potential for selection bias, measurement bias, and 
confounding  
Internal validity is rated “fair” if: Moderate potential for selection bias, measurement bias, and 
confounding 
Internal validity is rated “poor” if: Significant potential for selection bias OR measurement bias OR 
confounding  
Table 2: Criteria for Rating Internal Validity 
 
Grade Definition 
External validity is rated “good” if: Large and representative sample size,  standard protocols for 
research design  
External validity is rated “fair” if: Medium and somewhat representative sample size,  mostly 
standard protocols for research design 
External validity is rated “poor” if: Small and poorly representative sample size,  non-standard 
protocols for research design  
Table 3: Criteria for Rating External Validity 
 
Finally, I evaluate the overall strength of the evidence based on adapted criteria defined by 
Owens, Lohr, Atkins, et al. (4).  Unlike the quality assessment of each study, the strength of evidence 
assessment examines the quality of a body of studies.  A grade of “high” is reserved for a high 
confidence that the evidence reflects the true effect.  A grade of “low” is reserved for a low level of 
confidence that the evidence reflects the true effect (Table 4). 
Grade Definition 
High High confidence that the evidence reflects the true effect. 
Further research is very unlikely to change our confidence in 
the estimate of effect.  
Moderate Moderate confidence that the evidence reflects the true 
effect. Further research may change our confidence in the 
estimate of effect and may change the estimate.  
Low Low confidence that the evidence reflects the true effect. 
Further research is likely to change the confidence in the 
estimate of effect and is likely to change the estimate.  
Insufficient Evidence either is unavailable or does not permit a conclusion.  
Table 4: Strength of Evidence Grading  
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Results 
The search string retrieved 137 studies.  After reading the title and abstract of each study to 
determine the study’s relevance to the question of interest, fourteen articles remained.  After full-text 
review, seven studies remained: six identified from the search strategy and one from talking to an 
expert.  All seven studies were cross-sectional in nature, with only one having any form of masking.  
Four of the seven studies explicitly adjusted for confounders.  Six of the seven studies were either 
unfunded or funded by non-industry sources, and one study did not report a funding source.   Overall, 
no study received anything above a grade of above “fair” for internal validity.  One study did receive a 
“good” for generalizability.  Table 5 presents the relevant characteristics, results, and critical appraisal of 
the seven included studies.             
 
The Studies 
Five of the seven included studies concluded that industry sponsorship of clinical drug trials is 
associated with more publications that favor the investigational drug and/or the results of these trials 
get published at a lower frequency (5-9).  These five studies suffered from weaknesses of the study 
design and are of fair internal validity and fair to good generalizability.  Of these five studies, only the 
one by Als-Nielsen, Chen, Gluud, and Kjaergard masked the data collector to the sponsorship type and 
outcome of whether or not a study was “positive” or published (5).  While masking is likely not vital to 
the two studies defining a positive study as one with statistically significant results (7, 10), the one study 
that used more a subjective scale (5) and those that involve online searching for publications(7-9) may 
have more biased results.  For example, authors attempting to identify the publication status of a trial 
may not try as hard if they know that the trial is sponsored by industry.     
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The two remaining studies by Buchkowsky and Jewesson and Clifford, Barrowman, and Mohler 
concluded no association between industry sponsorship and publication characteristics (1, 11).  Like four 
of the five previous studies, these two studies did not use masking.  Importantly, neither study reported 
adjustments for potential confounders.  Additionally, while the Buchkowsky and Jewesson study used 
500 randomly selected trials, the study by Clifford et al. used a convenience sampling of 100.  Clifford et 
al. also failed to report a funding source.  Thus, I judged the Buchkowsky and Jewesson study to have fair 
internal validity and generalizability and the Clifford et al. study to have poor internal validity and 
generalizability (and excluded from further discussion).   
In terms of generalizability, the von Elm et al. study is the least generalizable study as it 
examines a cohort of protocols submitted to one Swiss university’s review committee (9).  While these 
the results may apply to other universities in Switzerland, it is uncertain if they apply to universities 
outside of Switzerland, and more importantly to protocols not submitted to universities for review.  
However, the studies by Ross, Mulvey, Hines, et al. and Bourgeois, Murthy, Keeneth, and Mandl 
examined a much more representative sample of all trials registered on ClinicalTrials.gov (7, 8). 
From the overall quality assessment of the included studies, there is more evidence for a 
relationship between funding source and selectively publishing, qualitatively and quantitatively.  
Discarding the one study with an internal validity rating of “poor”, five out of six studies provide 
evidence that funding by industry results in more selectively published studies.   A likely reason for the 
discrepancy between the Buchkowsky et al. study and the other five studies is that the former study 
used a less recent sample of publications: 1981-2000 vs. late 1990s-2000 for the other studies(1).  As 
noted, before 2001, major journal editors did not require disclosure of funding.   As such, over 20% of 
the studies the authors analyzed did not declare a funding source.  This could lead to a type II error.  
 
Strength of Evidence 
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 Overall, I judged the strength of evidence to be moderate—moderate confidence that the 
evidence reflects the true effect.  The use of a cross-sectional study design can introduce significant 
selection bias and potential for confounding.  Additionally, only one study used any masking.  However, 
most studies had a large sample size and adjusted for many relevant confounders. 
 
Discussion 
In conclusion, while the seven studies have their inherent weaknesses, the greater limitations 
and shortcomings in the two studies that did not find an association between sponsorship type and 
publication characteristics prompt us to be concerned that an association between industry sponsorship 
and selective publication does exist.  This conclusion agrees with two existing systematic reviews, which 
show an association between industry sponsorship and pro-industry conclusion, with an odds-ratios 
ranging from 3.60 (2.63-4.91) to 4.05 (2.98-5.51)(6, 12).  Of the seven studies included, two explicitly 
examined whether a mixed funding source has an influence selective publication.  Als-Nieslen et al. 
found that compared to clinical trials with non-industry sponsorship, clinical trials with mixed 
sponsorship did not favor the new treatment (5).  However, Bourgeois et al. found that compared to 
publications of trials without industry sponsorship, publications of trials mixed sponsorship still favor the 
experimental drug more often, 85% vs. 61%(7).  Given that only these two studies considered the 
category of mixed sponsorship as separate from industry-sponsored category and gave contradictory 
results, it is difficult to make any generalizations about mixed sponsorship and publication bias. 
 Though this small systematic review is subjected to selection bias since it focused only on 
articles from one database, the agreement of its conclusion with larger and more thorough systematic 
reviews supports its overall validity.  Another noted limitation is that all seven studies are cross-sectional 
in nature and are therefore much more open to selection bias and potential for confounding, despite 
attempts made to adjust for confounders.  Furthermore, causation cannot be established with 
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observational studies.  However, given the research question and the subject of the research, it is 
difficult, if not impossible, to use a different research design (e.g. a randomized controlled trial). 
Incomplete publications of clinical trials may occur for several reasons.  The investigators and/or 
sponsors may publish positive over negative results for financial and/or non-financial reasons.  Journals 
may also prefer to publish positive over negative results (13).  It is difficult to pinpoint the exact reason 
given the possible differences among trials conducted by industry and those conducted by non-industry 
(e.g. industry may only pursue trials with a higher chance of success, therefore their publications appear 
to favor the experimental drug more often; different journals, etc.).  However, if industry strategically 
selects more favorable trials to conduct, its overall rate of publishing should be higher than the rate for 
non-industry.  Since that does not appear to be the case, the results of this systematic review suggest 
that industry likely publishes less for reasons other than behaviors of journal reviewers and editors.    
One possible way to address the potential harms of selectively publishing is to increase the 
transparency of clinical trials.  FDAAA 2007 seeks to address this by making the results of applicable 
trials available to the public.  With this move, results will become available regardless of whether or not 
a clinical trial is published.  Lewis, Reichman, and So, however, argue that the mandatory disclosure of 
the results will only address a symptom of deeper structural problem of conflict of interest (14).  The 
authors recommend removing the direct link between clinical trial sponsor (the drug company) and the 
drug tester and making the federal government the primary funder of clinical trials.  While this approach 
would reduce cost, increase transparency, and greatly remove conflict of interest (e.g. a drug company 
will only fund trials of “beneficial” drugs like Viagra), such an approach will appear too radical to be 
politically feasible.     
Given the strong relationship between selective publishing and industry’s involvement in clinical 
trials of drugs, stakeholders should better regulate the relationship between industry and clinical trials.  
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While it is not sensible to bar all involvement from industry in medical research, ignoring this issue can 
lead to much harm. 
 
Study Als-Nielsen, Chen, Gluud, and 
Kjaergard (2003) 
Bhandrai, Busse, Jackowski, et 
al. (2004) 
Bourgeois, Murthy, 
Keeneth, and Mandl (2010) 
Funding Source Danish Centre for Evaluation 
and Health Technology 
Assessment 
Canadian Institutes of Health 
Research Fellowship Awards 
National Library of 
Medicine, National Institute 
of Health 
Study Question To explore  whether the 
association between funding 
and conclusions in randomized 
drug trials reflects treatment 
effects or adverse events 
To examine the association 
between industry funding and 
the statistical significance of 
results in recently published 
medical and surgical trials 
To describe characteristics 
of drug trials in 
ClinicalTrials.gov and 
examine whether funding 
source is associated with 
favorable published 
outcomes 
Study Design Cross-sectional Cross-sectional Cross-sectional 
Data Source Random sample of 167 
Cochrane reviews from 
Cochrane Library, May 2001. 
Trials published between Jan 
1999 and June 2001 in 8 and 5 
leading surgical and medical 
journals, respectively 
Trials registered at 
ClinicalTrials.gov between 
2000 and 2006. 
Sampling Strategy 
and Sample Size 
370 randomized drug trials 
chosen from 25 of the 167 
Cochrane reviews  
332 randomized controlled 
trials (RCTs) selected based on 
predefined quality criteria 
546 efficacy  or safety trials 
that studied 
anticholesteremics, 
antidepressants, 
antipsychotics, proton-
pump inhibitor, and 
vasodilators  
Selection Bias ++/+++ ++ ++ 
Measurement Bias + (masking present) ++ ++ 
Potential for 
Confounding 
++ ++ ++ 
Analysis: Adjusting 
for Confounders 
Adjusted for treatment effect, 
adverse events, methodological 
quality, sample size, whether 
preset sample size was 
estimated and reached, meta-
analysis, year of publication, and 
journal impact factor 
Adjusted for sample size, study 
design, and type of 
intervention 
Adjusted for drug class, 
approval status of 
indication, study phase, 
multicenter status, 
anticipated sample size, age 
of population, comparator 
type, and length of study 
Results Trials funded by for-profit 
organizations were more likely 
to recommend experimental 
drug as treatment choice, 
adjusted OR 5.3(2.0-14.4), 
compared with trials funded by 
non-profit organizations.  No 
difference for mixed funding.  
This association does not reflect 
treatment effects or adverse 
A statistically significant result 
in favor of new industry 
product, OR 1.8 (1.1-3.0) 
Publication within 24 
months of study completion 
ranged from 32.4% among 
industry-funded trials to 
56.2%  (p=0.005) among 
non-industry-funded trials.  
Industry-funded trials 
reported positive outcomes 
in 85.4% of publications, 
compared with 50.0% for 
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events. government-funded trials 
and 71.9% for non-profit or 
nonfederal organization 
funded trials (p<0.001).   
Internal Validity Fair Fair Fair 
Generalizability Fair Fair Fair/Good 
Table 5:  Summary of the Seven Included Studies 
Study Buchkowsky and Jewesson 
(2004) 
Clifford, Barrowman, and 
Mohler (2002) 
Ross, Mulvey, Hines, et al. 
(2009) 
Funding Source Unfunded 
 
None declared No external funding 
Study Question To characterize reported clinical 
trial funding sources, author-
industry affiliation, and clinical 
outcome trends over time. 
To examine the relationship 
between funding source, trial 
outcomes and reporting quality 
Characteristics of reporting 
optional data elements and 
publication rates among 
completed trials registered 
within ClinicalTrials.gov 
Study Design Cross-sectional Cross-sectional Cross-sectional 
Data Source Clinical trials published in 5 
influential medical journals 
(1981-2000) 
Five peer-reviewed, high 
impact factor general medical 
journals published between 
January 1999 and October 
2000 
Trials registered within 
ClinicalTrials.gov after 
December 31, 1999 and 
updated as completed by 
June 8, 2007, excluding 
phase I trials 
Sampling Strategy 
and Sample Size 
500 randomly selected trials of 
756 meeting inclusion criteria 
A convenience sample of 100 
RCTs, 20 RCTs/journal , 
restricted to studies of 
pharmaceuticals 
A random 10% subsample 
of the 7515 trials, with a 
registered end date before 
December 31, 2005 
Selection Bias ++ ++/+++ ++ 
Measurement Bias ++ ++ ++ 
Potential for 
Confounding 
++ ++/+++ ++ 
Analysis: Adjusting 
for Confounders 
No adjustments reported No adjustments reported No adjustment reported 
Results Study drug superiority over 
control intervention was 
reported in 103 (74%) of 
undeclared, 121 (67%) of non-
profit sponsor funded, 76 (73%) 
of industry funded, and 62 (81%) 
of the mixed study finding 
(p=0.159). 
30% of industry only sponsored 
trials vs. 15% of not-for profit 
only sponsored trials vs. 16% of 
mixed sponsored trials favored 
new drug (p=0.461) 
Trials sponsored by industry 
(40%) were less likely to be 
published when compared 
with non-
industry/nongovernment 
sponsored trials (56%, 
p<0.001), but no significant 
difference when compared 
with government sponsored 
trials (47%, p=0.22) 
Internal Validity Fair Poor Fair 
Generalizability Fair Poor Good 
Table 5 Continued:  Summary of the Seven Included Studies 
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Study von Elm, Rollin, Blumle, et al. 
(2008) 
Funding Source Research grant of the Swiss 
National Science Foundation 
Study Question To identify the factors associated 
with publication and non-
publication of results of a cohort 
of clinical trials 
Study Design Cross-sectional 
Data Source Protocols of randomized clinical 
trials of drug interventions 
submitted to the research ethics 
committee of University Hospital 
Bern, Switzerland, from 1988 to 
1998 
Sampling Strategy 
and Sample Size 
451 of 531 study protocols 
(exclusion not competed by 2006, 
stopped prematurely, never 
started, rejected) 
Selection Bias ++ 
Measurement Bias ++ 
Potential for 
Confounding 
++ 
Analysis: Adjusting 
for Confounders 
Adjusted for clinical specialty, 
type of study, planned sample 
size, number of centers involved, 
and international collaboration 
Results Non-commercial funding, OR 
2.42 (1.14-5.17), was associated 
with a full publication 
Internal Validity Fair 
Generalizability Poor/Fair 
Table 5 Continued:  Summary of the Seven Included Studies 
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